Introduction
cAMP acts as an important second messenger in many pathways regulating cell growth, differentiation, and apoptosis. Interestingly, depending on the cell type, diverging effects of cAMP on cell survival have been demonstrated. In B lymphocytes, cAMP has been shown to be an important mediator of growth arrest and apoptosis [1] [2] [3] , and similar effects have also been detected in T lymphocytes [4] and leukemic cell lines [5, 6] . In opposite to this, in neutrophils, increased levels of cAMP have been shown to delay apoptotic processes [7] [8] [9] [10] . For a long time, most of these functions were thought to be transmitted mainly via the PKA [3, 6, 9, 10] . However, a recent study in human neutrophils described PKA-independent, protective cAMP effects on cell survival as well [7] , suggesting a possible involvement of Epac. In line with this result, we could show recently that in the immature B lymphoma cell line WEHI-231, Epac proteins are critically involved BCR-induced growth arrest and apoptosis, acting via a potentiation of the signaling properties of the receptor [11] .
Therefore, we focused on the role of the Epac signaling pathway in apoptosis in human leukocytic cells. We report here that Epac activation inhibits leukocyte apoptosis significantly.
RESULTS AND DISCUSSION
First, we confirmed the expression of Epac in U937 cells (Fig. 1A) . To distinguish between PKA-and Epac-mediated effects, we confirmed the specificity of the Epac activators 8-pCPT and Sp by comparing their effects on the phosphorylation of VASP with the direct adenylyl cyclase activator forskolin. 8-pCPT-cGMP was used as a negative control. In contrast to forskolin (100 M), which stimulated VASP phosphorylation in a PKA-dependent manner, neither 8-pCPT (300 M) nor Sp (300 M) stimulated VASP phosphorylation (Fig. 1B) . These data confirmed the specificity of 8-pCPT and Sp as selective Epac activators in U937 cells and were allowed to clarify the effects of Epac activation on the TNF-␣-induced cell death pathway in U937 cells.
Epac activation inhibited TNF-␣-induced apoptosis significantly, as measured by PARP cleavage (Fig. 1C and Supplemental Fig. 1 ), caspase-3 processing (Fig. 1D) , Annexin V binding (Fig. 1E ), or nuclear chromatin condensation (Fig.  1F ). This antiapoptotic effect of Epac was observed over a period of 24 -48 h (Supplemental Fig. 2) .
Importantly, antiapoptotic effects of Epac activation were also detectable when different apoptose inducers, such as staurosporine (0.3 M), cycloheximide (10 g/ml), or etoposide (10 M), were used (Supplemental Figs. 3 and 4) .
In addition, we demonstrated that these effects were not restricted to the U937 cell line but also occurred in the human promyelocytic leukemia cell line HL-60 and in freshly isolated human CD45 ϩ mononuclear cells (Supplemental Fig. 4 ). Our findings confirm the results from other studies that cAMP inhibits leukocyte apoptosis. Clearly, the underlying mechanisms still remain controversial. Martin et al. [7] proposed an exclusion of PKA in this protection pathway against cell death, as the PKA inhibitors Rp-8-Br-cAMPS and H-89 could not prevent cAMP effects on apoptosis in neutrophils. However, these results are in contrast to the findings of Krakstad et al. [8] , who demonstrated that PKA is the only mediator of cAMP-induced protection against apoptosis in neutrophils. In their study, activation of Epac was not able to protect neutrophils against apoptosis, in contrast to selective activators of PKA. Possible differences in the signaling cascades between the cell types as well as differences between normal and leukemic cells might also be of importance and should be addressed in further studies.
From our data, we conclude that cAMP is able to inhibit leukocyte apoptosis significantly in an Epac-dependent way. As different cell types express PKA and Epac proteins in parallel but in variable amounts, an increase in cAMP levels can result in different net outcomes [18] . This depends on the particular distribution of both (or even more) cAMP effectors in the cell and might explain the varying or even opposite effects of cAMP in different cell types. 
